3 ms·
As someone who works in the industry, none of this seems accurate. - Marketing gets involved before phase 3. Phase 2 results are usually where the business de
by refurb 8y ago
As someone who works in the industry, none of this seems accurate.
- Marketing gets involved before phase 3. Phase 2 results are usually where the business decision to proceed to phase 3 are made, so commercial needs input on the trial design.
- Inclusion/exclusion criteria might be tweaked between phase 2 and 3, but they don't tend to drastically change as you're just asking for the trial to fail.
- Development works with the FDA to craft inclusion criteria that preserves the scientific rigor of the trials, but also allows for the broadest possible indication. In general, the FDA grants a much broader label than what is described in the trial criteria.
- danieltillett 8y agoYou have basically just summarised what I said :) I would not say the criteria are just “tweaked” between Phase 2 and 3 with any drug aimed at a broad market. It is always a balance between broadness and success and sometimes even the best in the business get it wrong. The FDA do allow a broader label than the exact trial criteria, but not massively so. If you restrict the Phase 3 to an identifiable sub-population good luck getting approval to expand to the larger population without running post-approval trials.
- refurb 8y agoWhere we disagree is on three points:(1) marketing gets involved well before phase 3,(2) most trial criteria don’t change that much between phase 2 and 3 [yes there are exceptions] and (3) the FDA allowing a broader label than inclusion criteria. As for the last one, most phase 3 trials have strict criteria: no other diseases, age limits, disease severity limits, etc. Those typically don’t make it into the label’s indication. I do agree that trials are designed to balance getting a positive outcome vs. the broadest population possible, but marketing isn’t the only one driving that.
- danieltillett 8y ago1. Yes marketing gets involved before Phase 3, but they tend to not have the clout they have going into Phase 3 - generally when it is unclear that you have something that works at all it hard for marketing to argue in favour of broadening the inclusions criteria. 2. I think your point 2 is where we disagree the most. We are really arguing over what is a significant change or not. 3. The FDA will be looser on some things like age and other diseases (within reason as you won’t get approval for children if you only trial in adults), but not on sub-groups. If you make your trial exclude on some disease sub-group criteria you are not going to get FDA approval to go outside that sub-group and sell to everyone with the disease. Who is driving trial broadening other than marketing? If I want the drug to succeed I want the trial population to be a homogeneous as possible and only include likely responders.
- aaavl2821 8y agoThe point about industry moving away from drugs that require large phase 3 studies to get approval in large populations is accurate. The vast majority of r&d these days goes to cancer -- increasingly genetically defined homogenous populations -- and rare disease. Smaller markets, but theoretically more tractable patient population (genetically defined population treated with genetically targeted tx) and higher pricing power